JP2013538796A5 - - Google Patents

Info

Publication number

JP2013538796A5

JP2013538796A5 JP2013522004A JP2013522004A JP2013538796A5 JP 2013538796 A5 JP2013538796 A5 JP 2013538796A5 JP 2013522004 A JP2013522004 A JP 2013522004A JP 2013522004 A JP2013522004 A JP 2013522004A JP 2013538796 A5 JP2013538796 A5 JP 2013538796A5

Authority

JP

Japan

Prior art keywords

antibody

amyloid

chain variable

variable region

cdr2

Prior art date

2011-07-29

Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)

Granted

Links

• Espacenet
• Global Dossier
• Discuss

• 125000003275 alpha amino acid group Chemical group 0.000 claims 17
• 230000004913 activation Effects 0.000 claims 13
• 238000000034 method Methods 0.000 claims 13
• 102000002574 p38 Mitogen-Activated Protein Kinases Human genes 0.000 claims 13
• 108010068338 p38 Mitogen-Activated Protein Kinases Proteins 0.000 claims 13
• 239000003814 drug Substances 0.000 claims 8
• 210000004027 cell Anatomy 0.000 claims 7
• 230000002025 microglial effect Effects 0.000 claims 7
• 229940079593 drug Drugs 0.000 claims 6
• 108010090849 Amyloid beta-Peptides Proteins 0.000 claims 5
• 102000013455 Amyloid beta-Peptides Human genes 0.000 claims 5
• 210000000274 microglia Anatomy 0.000 claims 5
• 206010002022 amyloidosis Diseases 0.000 claims 4
• 208000024827 Alzheimer disease Diseases 0.000 claims 3
• 238000004519 manufacturing process Methods 0.000 claims 3
• 230000001537 neural effect Effects 0.000 claims 3
• 230000000324 neuroprotective effect Effects 0.000 claims 3
• 230000035899 viability Effects 0.000 claims 3
• 238000004113 cell culture Methods 0.000 claims 2
• 239000003795 chemical substances by application Substances 0.000 claims 2
• 231100000189 neurotoxic Toxicity 0.000 claims 2
• 230000002887 neurotoxic effect Effects 0.000 claims 2
• DZHSAHHDTRWUTF-SIQRNXPUSA-N amyloid-beta polypeptide 42 Chemical compound C([C@@H](C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H](C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)NCC(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(O)=O)[C@@H](C)CC)C(C)C)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC(O)=O)C(C)C)C(C)C)C1=CC=CC=C1 DZHSAHHDTRWUTF-SIQRNXPUSA-N 0.000 claims 1
• 230000001054 cortical effect Effects 0.000 claims 1
• 231100000433 cytotoxic Toxicity 0.000 claims 1
• 230000001472 cytotoxic effect Effects 0.000 claims 1
• 239000003937 drug carrier Substances 0.000 claims 1
• 230000002438 mitochondrial effect Effects 0.000 claims 1
• 238000012544 monitoring process Methods 0.000 claims 1
• 230000003647 oxidation Effects 0.000 claims 1
• 238000007254 oxidation reaction Methods 0.000 claims 1
• 239000008194 pharmaceutical composition Substances 0.000 claims 1
• 230000007306 turnover Effects 0.000 claims 1